2013 Fiscal Year Annual Research Report
ＳＵＭＯ：ＳＢＭのタンパク質 － タンパク質相互作用阻害剤の発見
| Project/Area Number |
12F02509
|
|---|
| Research Institution | Institute of Physical and Chemical Research |
|---|
Principal Investigator |
VOET ARNOUT 独立行政法人理化学研究所, ライフサイエンス技術基盤研究センター, 国際特別研究員
|
|---|
| Project Period (FY) |
2012 – 2014-03-31
|
| Keywords | SUMO-SIM / Inhibitor / In Silico / ALPHAscreen / NMR / EleKit |
|---|
| Research Abstract |
Since the start of this project we have developed a computational approach to efficiently target protein-protein interactions, currently a hot topic in drug discovery. The sumo-sim interaction is essential in sumoylation and remains poorly understood. Therefore there is a need for a chemical probe to investigate this interaction. We have demonstrated the feasibility to target the SUMO-SIM interaction with druglike compounds for PPI inhibition as well as stimulation. These results have been published into 2 different publications. Given these promising results and after the development of the assays, a medium throughput screening experiment was set up and novel classes of compounds were identified that have possibly a more promising future for clinical usage. While this project is now terminated, it has opened a path to future research efforts as these compounds are interesting for optimization to analyse the sumo-SIM interactions and evaluate clinical usage (chemo and radio sensitization of cancer cells).
Furthermore parallel with this research a novel method to utilize electrostatics for drug discovery targeting protein-protein interactions was developed and evaluated. This new method was also employed during the SAMPL4 virtual screening challenge and helped in obtained the highest ranking score.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
everything went as anticipated.
|
| Strategy for Future Research Activity |
This research project has now been terminated as the research fellow changed to a RIKEN FPR fellowship.
|
